TNFRSF4 and glioma: Consistent with these observations, antitumor immunity mediated by coating tumor cells in situ with allogeneic antibodies was also dominated by CD4 + T cells34, and tumor inhibition in mice with orthothopically established glioma treated with tumor lysate and OX40-Fc fusion protein was CD4+, but not CD8, T cell-dependent, and was also B cell-dependent35.